ClinicalTrials.gg
Enrolling by invitationNCT06788340MOVE-ITUpdated Nov 6, 2026

MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease

A Phase 4 interventional study of PK-model to decide when to dose Vedolizumab and Ustekinumab in Inflammatory Bowel Diseases, Crohn Disease and Ulcerative Colitis, sponsored by Odense University Hospital. Enrolling by invitation at 6 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Odense University Hospital · Phase 4, Interventional, and Treatment

How we know

Updated Nov 6, 2026Now Enrolling by invitationStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Inflammatory Bowel Diseases with a site in Denmark — 7 open to participants now, 10 under way, 1 of them phase 3. Inflammatory Bowel Diseases · Denmark.

Planned enrollment
13th of 38
166 · median 111
Started
2026
with 2 others
Phase 4
6 of 65
2 open now
Registered
61st of 65
by date
Lead sponsor
3 of 65
Odense University Hospital

Among the 65 studies in Inflammatory Bowel Diseases with a site in Denmark, this one is the 13th largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 in phase 4, and was the 61st registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

7 of the 65 studies in Inflammatory Bowel Diseases with a site in Denmark are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Inflammatory Bowel Diseases with a site in Denmark, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate if dosage of Ustekinumab (UST) and Vedolizumab (VDZ) based on Model-Informed Precision Dosing (MIPD) is equally as efficient in keeping adults with Inflammatory Bowel Disease (IBD) in remission as management based on what the treating physician deems best. The main question is:

Is using pharmacokinetic-pharmacodynamic (PK-PD) models to predict the appropriate dose and dosing interval for VDZ and UST at least as effective as current practices in maintaining IBD remission.

As above mentioned the comparison-group is adults with IBD, treated with UST or VDZ, managed as the physician deems best.

Participants will:

Have blood and stool tests done, as well as answer a questionnaire 4th weekly Have their dosage frequency decided on either by the PK-model or as the physician deems best visit the clinic once every 24 weeks for checkups. Have an endoscopy done at completion of the study (if the disease is primarily located in the small intestine, MRI or capsule endoscopy will be used instead)

Read the detailed description

Patients will 4th weekly have their drug-concentration in blood measured (and if low, also antidrug antibodies). Hemoglobin, Albumin, CRP and white blood cell count will also be done, as well as a stool-sample for calprotectin measurement.

For the control group however, the clinicians and patients will be blinded for the results of the blood- and stool samples, and the samples for drug concentration will not get analyzed before end of study.

4th weekly they will also answer PRO2 questionnaire, as well as the VAS-F. 8th weekly they will in addition to above mentioned also answer the EQ-5D-5L questionnaire.

At inclusion, after 24 weeks, and at 48 weeks the patients will in addition to the above mentioned also answer the short IBDQ and WPAI questionnaires, as well as be seen in the outpatient clinic to obtain HBI or SCCAI score as applicable, as well as to document any changes in concomitant medication or diseases, and to register if any serious adverse events have presented.

At completion of the trial, patients will have a endoscopy done.

In one subprotocol, the investigators will include 20 patients from Odense to have an endoscopy at both inclusion and completion. Here they will also have biopsies taken from all segments of the colon, which will be stores in a biobank for future research.

In another subprotocol 20 patients will be included to have a intestinal ultrasound done at inclusion and completion.

In a biobank for future research the investigators will also store serum-samples, buffy coat, and stool samples collected at inclusion, after 24 and 48 weeks from all included patients.

03

Conditions studied

  • Inflammatory Bowel Diseases
  • Crohn Disease
  • Ulcerative Colitis

Keywords

  • MIPD
  • Model-Informed Precision Dosing
  • Therapeutic Drug Monitoring
  • TDM
  • Inflammatory Bowel Disease
  • Crohn's disease
  • Ulcerative colitis
  • Biologic therapy
  • Ustekinumab
  • Vedolizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ulcerative colitis or Crohn's disease. Diagnosed, according to universally acknowledged criteria, a minimum of 3 months prior to inclusion
  • Age ≥ 18
  • Stable treatment with VDZ or UST for at least 3 months prior to inclusion
  • Stable disease activity, mild activity is accepted, defined by fecal calprotectin ≤ 200, and a weighted PRO2 \< 14 for CD or a PRO2 ≤3 for UC
  • No change in medical therapy within 3 months prior to inclusion, as concomitant therapy with other immune suppressants is allowed (Azathioprine, 6-mercaptopurine, Methotrexate, 5-aminosalicylic acid)
  • The patient must be able to understand patient information material
  • The patient must be able to give informed written consent

Exclusion criteria

Exclusion Criteria:

  • Having a diagnose of indeterminate colitis
  • Having a stoma or pouch
  • Fistulizing disease being the primary reason for treatment with VDZ or UST
  • Expected eminent change of therapy
  • Expected need for surgical intervention within the coming 3 months
  • against continuing treatment with VDZ or UST, including prior acute or delayed infusion reaction to VDZ or UST
  • Any active infection requiring parenteral treatment, known infection with tuberculosis, (HIV) or hepatitis virus.
  • Any condition which the responsible physician finds incompatible with participation in the study
  • Patients unable to participate in the collection of symptoms scores
  • Patients who are pregnant or nursing at time of inclusion
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
166 participants (estimated)

Study arms

  • Experimental
    Model-informed precision dosing of Vedolizumab/Ustekinumab

    Patients will have blood- and stool samples collected, as well as date and time of drug administration every 4th week. All of these informations, in addition to some informations collected at inclusion, will be used in a PK-model to prescribe when the next dosage of drug should be administered to keep the patient in the therapeutic window.

    Drug: PK-model to decide when to dose Vedolizumab and Ustekinumab

  • No intervention
    Dosing of Vedolizumab/Ustekinumab by physicians best clinical assessment

    Patients will have blood- and stool samples collected every 4 weeks, but these will be blinded for the physicians. They are to be treated as regular patients, but will be seen every 24 weeks to collect clinical activity scores, register alterations in concomitant medication and possible serious adverse events.

Interventions

  • DrugPK-model to decide when to dose Vedolizumab and Ustekinumab

    the pharmacokinetic model will include information about inflammatory parameters both in blood- and fecal samples, as well as weight, sex, previous treatments and drug concentration.

06

What researchers measure

Primary outcomes

  1. The fraction of patients in steroid-free remission

    ((for CD defined by PRO2 ≤ 4, for UC defined by PRO2 = 0) AND a fecal calprotectin ≤200)

    Time frame: at the end of the observation period (48 weeks)

Secondary outcomes

  1. The fraction of the observation period (48 weeks) where the disease is in steroid-free remission

    for CD defined by patient reported outcome 2 (PRO2) stool frequency \<= 3 and abdominal pain \< = 1, for UC defined by PRO2, number of abnormal stools for the patient, bleeding from the rectum = 0) AND a fecal calprotectin ≤ 200.

    Time frame: this is registered every 4th week throughout the study duration of 48 weeks.

  2. The financial costs associated with the two treatment strategies over the observation period (12 months)

    expenditure on medicines (both expenditure on the purchase of medicines and expenditure on the administration of medicines), expenses for doctor visits / visits to a nurse, possibly expenses for hospitalization, possibly expenses for surgery, possibly expenses for sick leave and possibly expenses for early retirement. After end of study, the investigators will collect data on sick leave etc. from the national patient registry.

    Time frame: through study completion, an average of 48 weeks

  3. Endoscopic healing of the mucosa

    for CD assessed by Simple Endoscopic Score for Crohn's Disease (SES-CD) \<3; and for UC assessed on the basis of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)≤1. If disease is primarily located in the small intestine, MRI or capsule endoscopy will be used instead, and assessed by the simplified MaRIA score \<1 or Lewis score ≤135, respectively

    Time frame: at completion of study, approximately 48 weeks

  4. Changes in quality of life during the study period

    assessed by Short Inflammatory Bowel Disease Questionnaire (SIBDQ) difference between baseline and end of study. Improvement of quality of life indicated by a positive change of the SIBDQ. SIBDQ is collected at inclusion, week 24 and week 48. A higher the score, indicates a better outcome, Maksimum score of 70 points.

    Time frame: 48 weeks

  5. Quality of life as QALYs

    assessed by the EuroQol-5 dimensions-5 levels questionnaire (EQ-5D-5L) and converted to QALYs. The cost per QALY will also be calculated. EQ-5D-5L is collected every 8th week throughout the study. Score ranges from 5-25, a higher score indicating poorer quality of life.

    Time frame: 48 weeks

  6. Clinical Disease Activity

    assessed by Simplified Clinical Colitis Activity Index (SCCAI) for UC and Harvey-Bradshaw Index (HBI) for CD. These are collected at inclusion and every 24th week thereafter. SCCAI score ranges from 0-19, a higher score indicating a more severe disease activity. HBI score ranges from 0-20, a higher score indicating more severe disease activity.

    Time frame: 48 weeks

  7. Inflammatory burden over the observational period

    CRP, albumin, hemoglobin, leukocyte counts and fecal calprotectin. These will be collected every 4th week

    Time frame: 48 weeks

  8. Expenses for analysis of drug concentration

    patients will have drug concentrations analyzed every 4th week, the price of this will be collected

    Time frame: 48 weeks

  9. Expenses for drugs

    patients will typically administer sc VDZ every 4th to 2nd week, iv VDZ every 12th to 4th week and UST every 12th to 4th week

    Time frame: 48 weeks

  10. Drug persistency

    number of patients switching to another treatment during the study

    Time frame: 48 weeks

  11. Disease flares

    assessed by consumption of glucocorticoids or IBD-related surgery

    Time frame: 48 weeks

  12. Fatigue

    to assess if treating according to a PK-model results in less fatigue measured by Visual Analogue Scale to Evaluate Fatigue Severity (VAS-F). Patients are asked to register how fatigued they feel every 4th week throughout the study. The VAS-F is a visual analogue scale that goes from 0-10, 10 indicating severe fatigue.

    Time frame: 48 weeks.

  13. Disease impact on work productivity and performance of daily activities

    Assessed by difference in Work Productivity and Activity Impairment questionnaire (WPAI) scores and changes in scores between patients in the intervention- and control group. WPAI is collected at inclusion and every 24th week throughout the study. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

    Time frame: 48 weeks

07

Study locations

6 sites
  • Dept. of Gastrointestinal Diseases
    Aalborg, 9000, Denmark
  • Dept. of Internal Medicin
    Esbjerg, 6700, Denmark
  • Dept. of Gastrointestinal Diseases
    Hvidovre, 2650, Denmark
  • Dept. of medicine
    Nyborg, 5800, Denmark
  • Dept. of Gastrointestinal Diseases
    Odense, 5000, Denmark
  • Dept. of Medicine
    Vejle, 7100, Denmark
08

References and documents

Publications

  • Frimor C, Steenholdt C, Widigson ESK, Kjeldsen J, Larsen L, Burisch J, Joergensen MT, Halling ML, Kloft C, Ainsworth MA. MOdel-informed precision dosing (MIPD) of ustekinumab and VEdolizumab in inflammatory bowel disease: protocol for an Independent randomised, controlled, multicentre Trial (MOVE-IT). BMJ Open Gastroenterol. 2025 Dec 25;12(1):e001985. doi: 10.1136/bmjgast-2025-001985. PubMed 41453773 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data will possibly be shared, including clinical characteristics, laboratory test results, and patient-reported outcomes relevant to the study endpoints. Data will be available after publication of the main trial results and completion of any relevant follow-up studies. This is expected to occur approximately one year after the study's primary completion date. Data will be available for a minimum of 5 years following the publication of the trial results.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: will become available approximately March 2028 and will be available for at least 5 years

Access criteria: Data will be shared with qualified researchers conducting legitimate scientific inquiries, particularly those working within the field of inflammatory bowel disease (IBD) and therapeutic drug monitoring (TDM)

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

Of 33 non-industry phase 4 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 63. This study's planned 23 months is below that.

Counting every sponsor, half of 38 studies reached it within 38 months; a quarter within 21 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Sep 2025 → Jan 2026, primary completion Aug 2027 → Dec 2027 and completion Nov 2027 → Nov 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2025
First posted
Jan 23, 2025
StartActual
Jan 23, 2026was Sep 2025
Primary completionEst.
Dec 30, 2027was Aug 2027
CompletionEst.
Nov 30, 2028was Nov 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Nov 6, 2026
Start date
Sep 1, 2025→Jan 23, 2026 (actual)
Nov 6, 2026
Primary completion
Aug 30, 2027→Dec 30, 2027
Nov 6, 2026
Study completion
Nov 1, 2027→Nov 30, 2028
Nov 6, 2026
Contact
No study contact listed any more: removed c•••@rsyd.dk · •••7257; removed m•••@rsyd.dk
Nov 6, 2026
Site contacts
Changed at 6 sites. See the sites
Show 6 sites
  • Dept. of Gastrointestinal Diseases · Aalborg, DenmarkContact removed l•••@rn.dk · •••3572
  • Dept. of Internal Medicin · Esbjerg, DenmarkContact removed m•••@rsyd.dk · •••4527
  • Dept. of Gastrointestinal Diseases · Hvidovre, DenmarkContact removed j•••@regionh.dk · •••0363
  • Dept. of medicine · Nyborg, DenmarkContact removed c•••@rsyd.dk · •••7257
  • Dept. of Gastrointestinal Diseases · Odense, DenmarkContact removed c•••@rsyd.dk · •••7257
  • Dept. of Medicine · Vejle, DenmarkContact removed m•••@rsyd.dk · •••5500
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Enrolling by invitation
    Start date Sep 1, 2025→Jan 23, 2026 (now actual)
    Primary completion Aug 30, 2027→Dec 30, 2027
    Study completion Nov 1, 2027→Nov 30, 2028
    Contact No study contact listed any more: removed c•••@rsyd.dk · •••7257; removed m•••@rsyd.dk
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • Dept. of Gastrointestinal Diseases · Aalborg, DenmarkContact removed l•••@rn.dk · •••3572
    • Dept. of Internal Medicin · Esbjerg, DenmarkContact removed m•••@rsyd.dk · •••4527
    • Dept. of Gastrointestinal Diseases · Hvidovre, DenmarkContact removed j•••@regionh.dk · •••0363
    • Dept. of medicine · Nyborg, DenmarkContact removed c•••@rsyd.dk · •••7257
    • Dept. of Gastrointestinal Diseases · Odense, DenmarkContact removed c•••@rsyd.dk · •••7257
    • Dept. of Medicine · Vejle, DenmarkContact removed m•••@rsyd.dk · •••5500
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06788340
Responsible party
Sponsor
First posted
Jan 23, 2025
Start date
Jan 23, 2026
Primary completion
Dec 30, 2027 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Mark A Ainsworth, professor, DMSc
principal investigator · Odense University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion